Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update
February 17, 2017 12:09 PM EST
Wedbush assumed coverage on Ultragenyx Pharma (NASDAQ: RARE) with an Outperform rating and a price target of $88.00.
For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.
Shares of Ultragenyx Pharma closed at $76.82 yesterday.
...
More
February 17, 2017 8:13 AM EST
Jefferies analyst Gena Wang reiterates Buy rating and $109 price target on Ultragenyx Pharmaceuticals (NASDAQ: RARE), noting clinical progress across multiple initiatives, despite an "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.
Wang comments, "RARE 4Q16 EC was largely... More
February 16, 2017 4:13 PM EST
Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.75), $0.03 worse than the analyst estimate of ($1.72).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
...
More
